Home Peer Review Articles

Peer Review Articles

Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

Confocal Microscopy and Imaging Flow Cytometry – Tools for Selection of Antibodies to be...

Research articleAbstract Antibody-drug Conjugates (ADCs) are a growing class of targeted anti-cancer therapies, that combine the specific binding of an...
Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to...

Emerging Trends in Single-Use Technology in the Manufacturing of Antibody-Drug Conjugates

Single-use technology, designed for the manufacturing of biopharmaceutical products, has made major inroads over the last 30 years. First...

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

ADCs – Look Forward to a Potent Future

Antibody-drug conjugation (ADC) technology has been around for several decades but has yet to reach its full potential in...

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

The Nature and Nurturing of Hybrid Academic-Community Cancer Centers

Abstract With the increasing need for high-quality, state-of-the-art cancer care reaching more people than can be accommodated by National Cancer...

Drug-detached Naked Antibody Impairs ADC Efficacy

Abstract Armed with cytotoxic payloads, antibody-drug conjugate (ADC) becomes able to kill its naked-antibody-resistant tumor cell. When ADC circulates in...

Registration of Antibody Drug Conjugates

Abstract      Antibody Drug Conjugates (ADC) are a rapidly expanding area of pharma company pipelines. They combine the targeting of...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

Environmental Risk Assessment and New Drug Development

1.0 Abstract In our globalized world, human pharmaceutical residues and traces of other (chemical) down-the-drain contaminants have become an environmental...